Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $37.9 (market cap $29.26M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 257× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 64 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| QDTY | SYRE | |
|---|---|---|
Market Cap | $29.26M | $7.52B |
Volume | 13,576 | 1,441,031 |
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $108.92 |
52-Week Low | $36.57 | $22.18 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $38.94, down 0.36% with bearish technical signals from moving averages. The ETF maintains a consistent weekly dividend distribution strategy, with recent payments ranging from $0.19 to $0.30 per share. Technical indicators show mixed signals with RSI in neutral territory while ADX suggests weakening trend strength. The stock faces resistance at $40 with support clustered around $39.
The outlook remains cautious given bearish technical momentum and concentrated support levels. Dividend consistency provides income appeal, but technical weakness and tight trading range near current levels suggest limited near-term upside potential. Key risks include market volatility impact on covered call strategies and dependency on Nasdaq 100 performance.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
